COMP <GO>
NATR vs KROS // RETURN ON INVESTED CAPITAL (ROIC)
Nature's Sunshine Products Inc. (NASDAQ) VS. Keros Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NATR 1
— KROS 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: KROS
LAST: $12.07 (+0.42%) • MKT CAP: $211.5M
roic
28.90%
LAST: $10.83 (+0.65%) • MKT CAP: $213.3M
roic
85.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NATR VS. KROS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NATR | KROS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 72.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 28.90% | 85.00% | -56.10 | KROS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 13.35% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 5.20% | 27.70% | -22.50 | KROS | /operating-margins <GO> |
| Net Profit Margin | 4.10% | 35.70% | -31.60 | KROS | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 180.00% | -174.30 | KROS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.33 | 4.31 | +0.02 | NATR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.7 | 43.5 | -9.80 | KROS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $211.5M | $213.3M | -$1.8M | KROS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NATR REV | KROS REV | NATR GROSS % | KROS GROSS % | NATR FCF | KROS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $480.1M | $244.1M | 72.4% | — | $28.8M | $106.0M |
| FY 2024 | $454.4M | $3.5M | 71.5% | — | $14.3M | -$162.8M |
| FY 2023 | $445.3M | $151.0K | — | — | $41.2M | -$124.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NATR // BETA —
KROS // BETA —